Literature DB >> 12424844

Experimental autoimmune uveitides: multiple antigens, diverse diseases.

Grazyna Adamus1, Chi-Chao Chan.   

Abstract

Human autoimmune uveitides are diverse and complex. Animal models have been developed for studying the pathogenesis of uveitis because of the difficulties in obtaining tissues from a patient's inflamed eye for experiments. There are animal models for experimental uveitis that provoke inflammation of different tissues of the eye and represent different forms of uveitis. Since inflammatory cells can infiltrate any part of the uvea and spill over to nonuveal tissues, such as retina, various antigens have been used to induce uveitis. Most of those models that represent autoimmune forms of uveitis are induced with proteins specific for photoreceptor cells (S-antigen, IRBP, rhodopsin, recoverin, phosducin). Nonretinal antigens, including melanin-associated proteins and myelin basic protein, are also good inducers of uveitis in animals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424844     DOI: 10.1080/08830180212068

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  19 in total

Review 1.  Immunopathological aspects of age-related macular degeneration.

Authors:  Mrinali Patel; Chi-Chao Chan
Journal:  Semin Immunopathol       Date:  2008-02-26       Impact factor: 9.623

2.  Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate.

Authors:  O M Zack Howard; Hui Fang Dong; Shao Bo Su; Rachel R Caspi; Xin Chen; Paul Plotz; Joost J Oppenheim
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

Review 3.  Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment.

Authors:  Narendra Dhingra; Susan Kelly; Mohammed A Majid; Claire B Bailey; Andrew D Dick
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

4.  A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.

Authors:  Grazyna Adamus; Landon J Karren; Jeff Mooney; Gregory G Burrows
Journal:  Ophthalmic Res       Date:  2010-02-08       Impact factor: 2.892

5.  Enolase and arrestin are novel nonmyelin autoantigens in multiple sclerosis.

Authors:  Farzin Forooghian; Roy K Cheung; W Clay Smith; Paul O'Connor; Hans-Michael Dosch
Journal:  J Clin Immunol       Date:  2007-04-10       Impact factor: 8.317

Review 6.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

7.  Common genetic determinants of uveitis shared with other autoimmune disorders.

Authors:  Mary J Mattapallil; Azize Sahin; Phyllis B Silver; Shu-Hui Sun; Chi-Chao Chan; Elaine F Remmers; J Fielding Hejtmancik; Rachel R Caspi
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

8.  A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice.

Authors:  Giuseppina Pennesi; Mary J Mattapallil; Shu-Hui Sun; Dody Avichezer; Phyllis B Silver; Zaruhi Karabekian; Chella S David; Paul A Hargrave; J Hugh McDowell; W Clay Smith; Barbara Wiggert; Larry A Donoso; Chi-Chao Chan; Rachel R Caspi
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

9.  Inhibition of experimental autoimmune uveitis by amino acid copolymers.

Authors:  Hongen Yin; Barbara P Vistica; Chi-Chao Chan; Jack L Strominger; Igal Gery
Journal:  J Neuroimmunol       Date:  2009-09-11       Impact factor: 3.478

10.  Effective Arrestin-Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis.

Authors:  Madison Kyger; Aneta Worley; Jianya Huan; Hugh McDowell; W Clay Smith; Gregory G Burrows; Mary J Mattapallil; Rachel R Caspi; Grazyna Adamus
Journal:  Transl Vis Sci Technol       Date:  2013-02-05       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.